| 1 | four | 36,751 |
| 2 | follow-up.the | 11 |
| 3 | 3188 | 6 |
| 4 | gymnosperm | 6 |
| 5 | extlac | 5 |
| 6 | single-gender | 5 |
| 7 | pulse-labeling | 3 |
| 8 | undercoordinated | 3 |
| 9 | 10,662 | 2 |
| 10 | 16,242 | 2 |
| 11 | clinician-supported | 2 |
| 12 | daily-automated | 2 |
| 13 | mythimna | 2 |
| 14 | non-anaesthesia | 2 |
| 15 | 14,475 | 1 |
| 16 | 2-mm3 | 1 |
| 17 | 20,822 | 1 |
| 18 | 32nd-34th | 1 |
| 19 | 32nd-41st | 1 |
| 20 | 33rd-35th | 1 |
| 21 | 469,349 | 1 |
| 22 | 5-ala-pdt-treated | 1 |
| 23 | 58098 | 1 |
| 24 | 65,653 | 1 |
| 25 | 6th-17th | 1 |
| 26 | alpha-gal-negative | 1 |
| 27 | clinician-selected | 1 |
| 28 | d-galactosamine-sensitized | 1 |
| 29 | fractions/1-6 | 1 |
| 30 | fractions/2-3 | 1 |
| 31 | fractions/8 | 1 |
| 32 | lst,2nd,4th,6th | 1 |
| 33 | lung-second-primary-tumor-prevention | 1 |
| 34 | pariah | 1 |
| 35 | post-smoking-quit | 1 |
| 36 | pre-6th | 1 |
| 37 | pre-devonian | 1 |
| 38 | stat3-consensus-binding | 1 |
| 39 | to6 | 1 |
| 40 | two-eighth-grade | 1 |
| 1 | 10,662 | 2 |
| 2 | 14,475 | 1 |
| 3 | 16,242 | 2 |
| 4 | 2-mm3 | 1 |
| 5 | 20,822 | 1 |
| 6 | 3188 | 6 |
| 7 | 32nd-34th | 1 |
| 8 | 32nd-41st | 1 |
| 9 | 33rd-35th | 1 |
| 10 | 469,349 | 1 |
| 11 | 5-ala-pdt-treated | 1 |
| 12 | 58098 | 1 |
| 13 | 65,653 | 1 |
| 14 | 6th-17th | 1 |
| 15 | alpha-gal-negative | 1 |
| 16 | clinician-selected | 1 |
| 17 | clinician-supported | 2 |
| 18 | d-galactosamine-sensitized | 1 |
| 19 | daily-automated | 2 |
| 20 | extlac | 5 |
| 21 | follow-up.the | 11 |
| 22 | four | 36,751 |
| 23 | fractions/1-6 | 1 |
| 24 | fractions/2-3 | 1 |
| 25 | fractions/8 | 1 |
| 26 | gymnosperm | 6 |
| 27 | lst,2nd,4th,6th | 1 |
| 28 | lung-second-primary-tumor-prevention | 1 |
| 29 | mythimna | 2 |
| 30 | non-anaesthesia | 2 |
| 31 | pariah | 1 |
| 32 | post-smoking-quit | 1 |
| 33 | pre-6th | 1 |
| 34 | pre-devonian | 1 |
| 35 | pulse-labeling | 3 |
| 36 | single-gender | 5 |
| 37 | stat3-consensus-binding | 1 |
| 38 | to6 | 1 |
| 39 | two-eighth-grade | 1 |
| 40 | undercoordinated | 3 |
| 1 | 20,822 | 1 |
| 2 | 16,242 | 2 |
| 3 | 10,662 | 2 |
| 4 | fractions/2-3 | 1 |
| 5 | 65,653 | 1 |
| 6 | 2-mm3 | 1 |
| 7 | 14,475 | 1 |
| 8 | fractions/1-6 | 1 |
| 9 | to6 | 1 |
| 10 | fractions/8 | 1 |
| 11 | 3188 | 6 |
| 12 | 58098 | 1 |
| 13 | 469,349 | 1 |
| 14 | non-anaesthesia | 2 |
| 15 | mythimna | 2 |
| 16 | extlac | 5 |
| 17 | 5-ala-pdt-treated | 1 |
| 18 | daily-automated | 2 |
| 19 | undercoordinated | 3 |
| 20 | clinician-selected | 1 |
| 21 | clinician-supported | 2 |
| 22 | d-galactosamine-sensitized | 1 |
| 23 | two-eighth-grade | 1 |
| 24 | follow-up.the | 11 |
| 25 | alpha-gal-negative | 1 |
| 26 | stat3-consensus-binding | 1 |
| 27 | pulse-labeling | 3 |
| 28 | pariah | 1 |
| 29 | 32nd-34th | 1 |
| 30 | 33rd-35th | 1 |
| 31 | lst,2nd,4th,6th | 1 |
| 32 | pre-6th | 1 |
| 33 | 6th-17th | 1 |
| 34 | gymnosperm | 6 |
| 35 | pre-devonian | 1 |
| 36 | lung-second-primary-tumor-prevention | 1 |
| 37 | single-gender | 5 |
| 38 | four | 36,751 |
| 39 | post-smoking-quit | 1 |
| 40 | 32nd-41st | 1 |